S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
The REAL Reason Americans Keep Falling Behind (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
The REAL Reason Americans Keep Falling Behind (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
The REAL Reason Americans Keep Falling Behind (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
The REAL Reason Americans Keep Falling Behind (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
The REAL Reason Americans Keep Falling Behind (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
The REAL Reason Americans Keep Falling Behind (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
The REAL Reason Americans Keep Falling Behind (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
The REAL Reason Americans Keep Falling Behind (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:ACRS

Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

$1.19
-0.02 (-1.65%)
(As of 02/23/2024 ET)
Today's Range
$1.17
$1.24
50-Day Range
$0.92
$1.28
52-Week Range
$0.59
$12.93
Volume
720,578 shs
Average Volume
2.07 million shs
Market Capitalization
$84.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.17

Aclaris Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
1,846.8% Upside
$23.17 Price Target
Short Interest
Healthy
8.94% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of Aclaris Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.63) to ($1.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

698th out of 941 stocks

Pharmaceutical Preparations Industry

321st out of 432 stocks


ACRS stock logo

About Aclaris Therapeutics Stock (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Stock Price History

ACRS Stock News Headlines

AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
The #1 Energy Passive Income Investment for 2023
It's not a stock, bond or private company... But this little-known alternative investment could hand you BIG MONTHLY INCOME from the oil and gas surge in 2023.
The Analyst Landscape: 4 Takes On Aclaris Therapeutics
Aclaris Therapeutics to Reduce Workforce by Nearly Half
Aclaris Therapeutics Provides Corporate Update
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
2/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACRS
Employees
100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$23.17
High Stock Price Target
$38.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+1,846.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$-86,910,000.00
Net Margins
-534.83%
Pretax Margin
-534.83%

Debt

Sales & Book Value

Annual Sales
$29.75 million
Book Value
$2.96 per share

Miscellaneous

Free Float
66,901,000
Market Cap
$84.24 million
Optionable
Optionable
Beta
0.20

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Neal S. Walker D.O. (Age 54)
    M.D., Co-Founder, President, Chairman & Interim CEO
    Comp: $955.69k
  • Dr. Joseph Monahan Ph.D. (Age 67)
    Chief Scientific Officer
    Comp: $600.02k
  • Mr. Kevin Balthaser (Age 37)
    Chief Financial Officer
  • Mr. Matthew Rothman J.D.
    General Counsel & Corporate Secretary
  • Dr. Jon Jacobsen Ph.D.
    Senior Vice President of Chemistry
  • Mr. James Loerop (Age 60)
    Chief Business Officer














ACRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACRS, but not buy additional shares or sell existing shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price target for 2024?

8 brokerages have issued 12 month target prices for Aclaris Therapeutics' stock. Their ACRS share price targets range from $9.00 to $38.00. On average, they expect the company's share price to reach $23.17 in the next twelve months. This suggests a possible upside of 1,846.8% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2024?

Aclaris Therapeutics' stock was trading at $1.05 at the start of the year. Since then, ACRS stock has increased by 13.3% and is now trading at $1.19.
View the best growth stocks for 2024 here
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its earnings results on Monday, November, 6th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.07. The biotechnology company had revenue of $9.30 million for the quarter, compared to analysts' expectations of $1.57 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 64.53% and a negative net margin of 534.83%. The company's revenue was down 51.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.30) EPS.

What ETFs hold Aclaris Therapeutics' stock?
What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.67%), Bain Capital Life Sciences Investors LLC (4.94%), Velan Capital Investment Management LP (2.49%), GSA Capital Partners LLP (2.24%), Monaco Asset Management SAM (1.38%) and BML Capital Management LLC (0.92%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kamil Ali-Jackson, Kevin Balthaser and Neal Walker.
View institutional ownership trends
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACRS) was last updated on 2/24/2024 by MarketBeat.com Staff